Backs view of mid-single digit percentage decline in FY23 revenue versus reported full year 2022, consensus $9.6B. As of June 30, Biogen had cash, cash equivalents, and marketable securities totaling $7.286B and $6.285B in total debt, resulting in net cash of $1.002B. No shares of the company’s common stock were repurchased in the second quarter of 2023. As of June 30, there was $2.050B remaining under the share repurchase program authorized in October 2020, the company noted.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BIIB: